Literature DB >> 16308679

[Cytokine CXCL13--a possible early CSF marker for neuroborreliosis].

T A Rupprecht1, U Koedel, B Angele, V Fingerle, H-W Pfister.   

Abstract

The definitive diagnosis of acute neuroborreliosis (NB) is based upon the presence of lymphomonocytic CSF pleocytosis and intrathecal Borrelia burgdorferi (B.b.)-specific antibody production (expressed by an antibody index of >2). However, the latter might be absent in early stages of the disease. Now a recently discovered additional CSF marker-the cytokine CXCL13-was found to be positive in every initial CSF sample from patients with NB and therefore could be a valuable tool for early diagnosis and initiation of antibiotic therapy. We report an unusual case of NB in a patient with a history of metastatic carcinoma of the prostate and unilateral polyradiculitis. While no intrathecal B.b.-specific antibody production could be demonstrated initially, the CSF CXCL13 level was high (>500 ng/g vs <1.7 ng/g in healthy controls). During the course of the disease, the antibody index turned positive (4.8) and the patient responded to antibiotic therapy, thus confirming the diagnosis. In this case, measuring CXCL13 in the CSF would have led to earlier diagnosis and treatment of NB.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16308679     DOI: 10.1007/s00115-005-2021-7

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  9 in total

1.  Dural metastases in prostate cancer.

Authors:  A M H Bentley; J C Keen
Journal:  Clin Oncol (R Coll Radiol)       Date:  2003-05       Impact factor: 4.126

Review 2.  Intracranial metastases as the first manifestation of prostate cancer.

Authors:  M A Sutton; H L Watkins; L K Green; D Kadmon
Journal:  Urology       Date:  1996-11       Impact factor: 2.649

3.  The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis.

Authors:  T A Rupprecht; H W Pfister; B Angele; S Kastenbauer; B Wilske; U Koedel
Journal:  Neurology       Date:  2005-08-09       Impact factor: 9.910

4.  The nervous system as ectopic germinal center: CXCL13 and IgG in lyme neuroborreliosis.

Authors:  Kavitha Narayan; Donna Dail; Libin Li; Diego Cadavid; Sheela Amrute; Patricia Fitzgerald-Bocarsly; Andrew R Pachner
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

Review 5.  Lyme borreliosis: basic science and clinical aspects.

Authors:  H W Pfister; B Wilske; K Weber
Journal:  Lancet       Date:  1994-04-23       Impact factor: 79.321

6.  BCA-1 is highly expressed in Helicobacter pylori-induced mucosa-associated lymphoid tissue and gastric lymphoma.

Authors:  L Mazzucchelli; A Blaser; A Kappeler; P Schärli; J A Laissue; M Baggiolini; M Uguccioni
Journal:  J Clin Invest       Date:  1999-11       Impact factor: 14.808

Review 7.  Follicular stromal cells and lymphocyte homing to follicles.

Authors:  J G Cyster; K M Ansel; K Reif; E H Ekland; P L Hyman; H L Tang; S A Luther; V N Ngo
Journal:  Immunol Rev       Date:  2000-08       Impact factor: 12.988

8.  Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial.

Authors:  Vassilis Georgoulias; Alexandros Ardavanis; Athina Agelidou; Maria Agelidou; Vassilis Chandrinos; Emilia Tsaroucha; Michael Toumbis; Charalambos Kouroussis; Konstantinos Syrigos; Aristidis Polyzos; Nikolaos Samaras; Pavlos Papakotoulas; Charalambos Christofilakis; Nicolaos Ziras; Athanasios Alegakis
Journal:  J Clin Oncol       Date:  2004-07-01       Impact factor: 44.544

9.  Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis.

Authors:  H Tumani; G Nölker; H Reiber
Journal:  Neurology       Date:  1995-09       Impact factor: 9.910

  9 in total
  12 in total

1.  [CXCL13: a biomarker for acute Lyme neuroborreliosis: investigation of the predictive value in the clinical routine].

Authors:  T A Rupprecht; C Lechner; H Tumani; V Fingerle
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 2.  [Bacterial infections of the central nervous system].

Authors:  M Klein; H-W Pfister
Journal:  Nervenarzt       Date:  2010-02       Impact factor: 1.214

3.  Discriminating Lyme neuroborreliosis from other neuroinflammatory diseases by levels of CXCL13 in cerebrospinal fluid.

Authors:  N D van Burgel; F Bakels; A C M Kroes; A P van Dam
Journal:  J Clin Microbiol       Date:  2011-03-02       Impact factor: 5.948

Review 4.  [Neuroborreliosis - Diagnostics, treatment and course].

Authors:  R Dersch; S Rauer
Journal:  Nervenarzt       Date:  2017-04       Impact factor: 1.214

Review 5.  [Neuroborreliosis].

Authors:  R Kaiser; V Fingerle
Journal:  Nervenarzt       Date:  2009-10       Impact factor: 1.214

Review 6.  The pathogenesis of lyme neuroborreliosis: from infection to inflammation.

Authors:  Tobias A Rupprecht; Uwe Koedel; Volker Fingerle; Hans-Walter Pfister
Journal:  Mol Med       Date:  2008 Mar-Apr       Impact factor: 6.354

7.  Diagnostic value of cytokines and chemokines in lyme neuroborreliosis.

Authors:  T Cerar; K Ogrinc; S Lotric-Furlan; J Kobal; S Levicnik-Stezinar; F Strle; E Ruzić-Sabljic
Journal:  Clin Vaccine Immunol       Date:  2013-08-14

Review 8.  Laboratory Diagnosis of Lyme Borreliosis.

Authors:  John A Branda; Allen C Steere
Journal:  Clin Microbiol Rev       Date:  2021-01-27       Impact factor: 26.132

9.  The chemokine CXCL13 is a key regulator of B cell recruitment to the cerebrospinal fluid in acute Lyme neuroborreliosis.

Authors:  Tobias A Rupprecht; Andreas Plate; Michaela Adam; Manfed Wick; Stefan Kastenbauer; Caroline Schmidt; Matthias Klein; Hans-Walter Pfister; Uwe Koedel
Journal:  J Neuroinflammation       Date:  2009-12-30       Impact factor: 8.322

10.  CXCL13 may improve diagnosis in early neuroborreliosis with atypical laboratory findings.

Authors:  Johannes P Borde; Simone Meier; Volker Fingerle; Christiane Klier; Johannes Hübner; Winfried V Kern
Journal:  BMC Infect Dis       Date:  2012-12-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.